Analyst will focus on phase III studies and travel vaccines in Bavarian report

On Monday, Bavarian Nordic will release its first quarterly report for the year, and a Sydbank analyst is waiting in suspense to hear more about two phase III vaccine studies and how well travel vaccines performed.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

In the year 2022, Bavarian Nordic will be conducting two phase III studies – and investors are keeping a keen eye on news about either, when the biotech firm publicizes figures from its first financial quarterly on Monday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs